Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas

Molecular Cancer Therapeutics

Volumn 4, Issue 9, 2005, Pages 1293-1302

  Yuan, Liya ^a   Choi, Kihang ^b   Khosla, Chaitan ^b   Zheng, Xiao ^a   Higashikubo, Ryuji ^a   Chicoine, Michael R ^a   Rich, Keith M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; ANTINEOPLASTIC AGENT; BIM PROTEIN; CARMUSTINE; CELL PROTEIN; DANSYLCADAVERINE; DNA NUCLEOTIDYLEXOTRANSFERASE; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; KCA 075; KCC 009; PROTEIN BAD; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2 INHIBITOR; PROTEIN KINASE B; SURVIVIN; TUBULIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; AZO COMPOUND; BCL 2 BINDING PROTEIN, BIM; BCL-2-BINDING PROTEIN, BIM; BIRC5 PROTEIN, HUMAN; CADAVERINE; DRUG DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; GUANINE NUCLEOTIDE BINDING PROTEIN; MEMBRANE PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; TRANSGLUTAMINASE 2; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; CHEMOSENSITIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LETHAL DOSE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BRAIN TUMOR; CELL CULTURE; CELL DEATH; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYNTHESIS;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; AZO COMPOUNDS; BRAIN NEOPLASMS; CADAVERINE; CARMUSTINE; CELL DEATH; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GLIOBLASTOMA; GLYCOGEN SYNTHASE KINASE 3; GTP-BINDING PROTEINS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TRANSGLUTAMINASES; TUMOR CELLS, CULTURED;

EID: 33644668017     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0328     Document Type: Article

References (35)

1. Cairncross JG, MacDonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23:360-4.
2. Donahue B, Scott CB, Nelson JS, et al. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys 1997;38:911-4.
3. Nutt CL, Noble M, Chambers AF, Cairncross JG. Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy. Cancer Res 2000; 60:4812-8.
4. Lytle RA, Jiang Z, Zheng X, Rich KM. BCNU down-regulates anti-apoptotic proteins Bcl-xL and Bcl-2 in association with cell death in oligodendroglioma-derived cells. J Neuro-oncol 2004;68:233-41.
5. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9.
6. Verderio EA, Telci D, Okoye A, Melino G, Griffin M. A novel RGZD-independent cell adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis. Biol Chem 2003;278: 42604-14.
7. Hausch F, Halttunen T, Maki M, Khosla C. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase. Chem Biol 2003; 10:225-31.
8. Choi K, Siegel M, Piper J, et al. Chemistry and biology /of dihydro-isoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 2005; 12:469-75.
9. Rohloff JC, Rubbinsun J, Gardner JO. Bromonitrile oxide [3+2] cycloadditions in water. Tetrahedron Lett 1992;33:3113-6.
10. Lesort M, Tucholski J, Zhang J, Johnson GVW. Impaired mitochondrial function results in increased tissue transglutaminase activity in situ. J Neurochem 2000;75:1951-61.
11. Komanishi T. Brain tumors induced with Rous sarcoma virus, Schmidt-Ruppin strain. I. Induction of brain tumors in adult mice with Rous chicken sarcoma cells. J Exp Med 1967;37:461-74.
12. Chicoine MR, Won EK, Zahner M. Intratumoral injection of lipopolysaccharide causes regression of subcutaneously implanted mouse DBT glioblastoma multiforme. J Neurosurg 2001;48:607-15.
13. Thomazy VA, Davies PJ. Expression of tissue transglutaminase in the developing chicken limb is associated both with apoptosis and endochondral ossification. Cell Death Differ 1999;6:146-54.
14. Piacentini M, Autuori F. Immunohistochemical localization of tissue transglutaminase and Bcl-2 in rat uterine tissues during embryo implantation and post-partum involution. Differentiation 1994;5:51-61.
15. h/tissue transglutaminase II. J Biol Chem 2001; 276:20673-8.
16. Antonyak MA, Boehm JE, Cerione RA. Phosphoinositide 3-kinase activity is required for retinoic acid-induced expression and activation of the tissue transglutaminase. J Biol Chem 2002;277:14712-6.
17. Antoyak MA, Miller AM, Jansen JM, et al. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibits doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem 2004;279:41461-7.
18. McCormick F. Survival pathways meet their end. Nature 2004;428: 267-9.
19. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 2001;61: 6674-8.
20. Li B, Chang CM, Yuan M, McKenna WG, Shu HK. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 2003;63:7443-50.
21. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998;8:1195-8.
22. Davies MA, Lu Y, Sano T, et al. Adenoviral transgene expression of MMAC/ PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 1998;58:5285-90.
23. Datta SR, Dudek H, Tao T, et al. Akt phosphorylation of Bad couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
24. Tan DA, Teo WL, Smith DR. Expression of survivin in primary glioblastoma. J Cancer Res Clin Oncol 2002; 128:302-6.
25. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004;29:95-102.
26. O'Connor L, Strasser A, O'Reilly LA, et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EBMO J 1998; 17:384-95.
27. Hsu SY, Lin P, Hsueh AJ. BOD (Bcl-2-related ovarian death gene) is an ovarian BH3 domain-containing proapoptotic Bcl-2 protein capable of dimerization with diverse antiapoptotic Bcl-2 members. Mol Endocrinol 1998; 12:1432-40.
28. Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and post-translation control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002;9:505-12.
29. Bouillet P, Metcalf D, Huang DC, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999;286:1735-8.
30. Jiang Z, Zheng X, Lytle RA, Higashikubo R, Rich KM. Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells. J Neurochem 2004;89:168-78.
31. Walker MD, Green SB, Byar DP, et al. Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Eng J Med 1980;303:1323-9.
32. Kornblith PL, Smith BH, Leonard LA. Response of cultured human brain tumors to nitrosoureas: correlation with clinical data. Cancer 1981; 47:255-65.
33. Thomas DG, Darling JL, Paul EA, et al. Assay of anticancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro hemosensitivity in patients with malignant cerebral gliomas. Br J Cancer 1985;51:525-32.
34. Simstein R, Burow M, Parker A, Weldon C, Beckman B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood) 2003; 228:995-1003.
35. Cusack JC, Jr. Overcoming antiapoptotic responses to promote chemosensitivity in metastatic colorectal cancer to the liver. Ann Surg Oncol 2003; 10:852-62.